CMTA has partnered with Shift Pharmaceuticals to evaluate an antisense oligonucleotide (ASO) for the treatment of CMT1A. The collaboration will use CMTA-STAR preclinical testing capabilities to assess the therapeutic potential of an ASO designed to reduce PMP22 overexpression and support advancement toward clinical trials.
Schwann Cell-Targeted Gene Therapy Approaches to Treat CMT1A and Other Demyelinating Neuropathies
With CMTA support of over $160,000, an international team of researchers is developing genetic therapy...
Development of a new CMT1A research toolbox: an alternative human stem cell-based strategy
With CMTA support of $98,890, researchers at Hasselt University in Belgium, led by Esther Wolfs,...
